Ask AI
ALKPos Advanced NSCLC

CE / CME

Targeted Therapy TALK: Translating the Latest Advances Into Precision Care for ALK-Positive Advanced NSCLC

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Nurse Practitioners/Nurses: 1.00 Nursing contact hour

Pharmacists: 1.00 contact hour (0.1 CEUs)

Physicians: maximum of 1.00 AMA PRA Category 1 Credit

Released: June 17, 2025

Expiration: December 16, 2025

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

In your current practice, how often do you request RNA sequencing for actionable molecular biomarkers in advanced NSCLC, assuming adequate biopsy tissue?

2.

Case Continued: Patient With Metastatic NSCLC



  • 27-yr-old female presents to urgent care with 3 mo of increased fatigue, dry cough, and self-palpated supraclavicular fullness

  • CT: 1.2-cm cavitary lesion in RUL; innumerable bilateral pulmonary nodules; diffuse lymphadenopathy; ultrasound-guided supraclavicular biopsy: metastatic NSCLC; MRI brain: no intracranial disease

  • PD-L1 70; tissue molecular testing pending

  • ctDNA assay sent in clinic at first visit

  • 1 wk later: ctDNA demonstrates EML4:ALK fusion

  • Tissue RNA fusion confirms EML4:ALK fusion; returns approximately 2 wks after ctDNA assay results

In your current practice, what would you consider to be the optimal first-line therapy for this patient?

3.

Which of the following adverse events that occurs in most patients treated with lorlatinib should be monitored for prior to and after initiation of treatment?